Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens by Wyen, C et al.
 1
Cytochrome P450 2B6 (CYP2B6) and Constitutive androstane 
receptor (CAR) polymorphisms are associated with early 
discontinuation of efavirenz - containing regimens. 
 
Christoph Wyen1, Heidy Hendra1, Marco Siccardi2, Martin Platten1, Hans Jaeger3, 
Thomas Harrer4, Stefan Esser5, Johannes R. Bogner6, Norbert H. Brockmeyer7, 
Bernhard Bieniek8, Juergen Rockstroh9, Christian Hoffmann10, Albrecht Stoehr11, 
Claudia Michalik12, Verena Dlugay13, Alexander Jetter14, Heribert Knechten15, 
Hartwig Klinker16, Adriane Skaletz-Rorowski17, Gerd Fätkenheuer1, Deirdre Egan2, 
David J Back2, Andrew Owen2* on behalf of the German Competence Network for 
HIV/AIDS† 
 
1Department of Internal Medicine, University of Cologne, Cologne, Germany,  
2Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK, 
3HIV Research and Clinical Care Centre Munich, Munich, Germany, 
4Department of Internal Medicine 3, University Hospital Erlangen, University of 
Erlangen-Nuremberg, Germany 
5Deparment of Dermatology, University of Essen, Essen, Germany,  
6Department of Internal Medicine, University of Munich, Munich, Germany,  
7Department of Dermatology, Venerology and Allergology Ruhr-Universität Bochum, 
Bochum, Germany, 
8PraxisCityOst, Berlin, Germany, 
9Department of Internal Medicine, University of Bonn, Bonn, Germany,  
10IPM Study Center, Hamburg/University of Schleswig Holstein, Kiel, Germany, 
11ifi-Institute for interdisciplinary medicine, Hamburg, Germany,  
12Clinical Trials Centre Cologne ZKS, University of Cologne, Köln, Germany, 
13Institute of Medical Statistics, Informatics and Epidemiology, University of Cologne, 
Köln, Germany,  
14Department of Clinical Pharmacology and Toxicology, Department of Internal 
Medicine, University Hospital Zurich, Zürich, Switzerland,   
15PZB Blondelstrasse, Aachen, Germany, 
16Department of Internal Medicine, University of Würzburg, Würzburg, Germany 
17Competence Network for HIV/AIDS, Ruhr-Universität Bochum, Bochum, Germany 
 
†Members of the German Competence Network for HIV/AIDS are listed in the 
Acknowledgement 
 
Author for correspondence and reprints: Dr A Owen, Department of 
Pharmacology and Therapeutics, University of Liverpool, 70 Pembroke Place, Liverpool, 
L69 3GF, U.K.  
Tel No +44 (0) 151 794 5919 
Fax No + 44 (0) 151 794 5656 
E-mail: aowen@liv.ac.uk  
 
Running headline: CYP2B6 and CAR SNPs and efavirenz discontinuation 
 
Source of financial support 
This work was funded by the UK Medical Research Council, the German Competence 
Network for HIV/AIDS and the BMBF (Bundesministerium für Bildung und Forschung; 
Grant: 01 KI 0771). 
 
Text word count: 2671
 2
Synopsis 
Objectives: Cytochrome P450 2B6 (CYP2B6) is responsible for metabolic clearance of 
efavirenz and single nucleotide polymorphisms (SNPs) in the CYP2B6 gene are 
associated with efavirenz pharmacokinetics. Since the constitutive androstane receptor 
(CAR) and the pregnane X receptor (PXR) correlate with CYP2B6 in liver and a CAR 
polymorphism (rs2307424) and smoking correlate with efavirenz plasma concentrations, 
we investigated their association with early (<3 months) discontinuation of efavirenz 
therapy. 
 
Methods: 373 patients initiating therapy with an efavirenz based regimen were included 
(278 White and 95 Black; 293 male). DNA was extracted from whole blood and 
genotyping for CYP2B6 (516G>T, rs3745274), CAR (540C>T; rs2307424) and PXR 
(44477T>C, rs1523130; 63396C>T, rs2472677; 69789A>G, rs763645) were conducted. 
Binary logistic regression by backwards method was used to assess the influence of 
SNPs and demographics on early discontinuation. 
 
Results: Of the 373 patients, 131 withdrew from therapy within the first 3 months. Black 
ethnicity (Odds Ratio (OR) = 0.27; p = 0.0001), CYP2B6 516TT (OR = 2.81; p = 0.006), 
CAR rs2307424 CC (OR = 1.92; p = 0.007) and smoking status (OR = 0.45; p = 0.002) 
were associated with discontinuation within three months. 
 
Conclusions: These data indicate that genetic variability in CYP2B6 and CAR contribute 
to early treatment discontinuation for efavirenz-based antiretroviral regimens. Further 
studies are now required to define the clinical utility of these associations.  
 
Key words: Pharmacogenetics, pharmacokinetics, metabolism, drug disposition. 
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Introduction 
Efavirenz treatment is associated with Central nervous system (CNS) or 
neuropsychiatric side effects in a large proportion of patients (~25%–70%) and can give 
symptoms such as dizziness, headache, abnormal dreams and sleep disturbance, 
mood changes, anxiety, dizziness and impaired concentration. 1-3 CNS side effects 
normally arise in the first days/weeks of treatment and for a small minority of patients 
can be prolonged for several months or emerge after numerous weeks of treatment 4 
but do not always result in discontinuation of therapy. Discontinuation of efavirenz-
containing regimens has been reported with various frequencies in different studies, 
ranging from 5 to 20%, and neuropsychiatric side effects account for the majority of 
discontinuation cases. 3, 5-7 The causes of CNS and other side effects related to 
efavirenz containing regimens have not been fully characterised but some studies 
indicate that neuropsychiatric side effects are associated with high plasma 
concentrations, particularly in the first weeks of treatment. 8-10 
 
Phase I metabolism of efavirenz is predominantly catalysed by cytochrome P450 2B6 
(CYP2B6) and single nucleotide polymorphisms (SNPs) within the CYP2B6 gene are 
associated with altered hepatic CYP2B6 expression and activity.11 The role of the 
516G>T (rs3745274) SNP in pharmacokinetics of efavirenz has been studied 
extensively.12-19 In addition to CYP2B6, a secondary route of phase I metabolism of 
efavirenz is catalysed by CYP2A6 and CYP2A6 polymorphisms have also recently been 
identified as determinants of efavirenz plasma concentrations.20-23 
 
The primary metabolite of phase I metabolism, 8-hydroxy efavirenz then undergoes 
glucuronidation prior to excretion in urine and bile. This phase II metabolism has 
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recently been attributed to UDP-glucuronosyltransferase isoform 2B7 (UGT2B7) 24 and 
evidence is emerging that UGT2B7 polymorphisms are also associated with efavirenz 
plasma concentrations. 20 Hence, a thorough knowledge of the routes of metabolism 
and elimination of efavirenz have successfully identified candidate genes for 
pharmacogenetic studies. 
 
The constitutive androstane receptor (CAR) and the preganane X receptor (PXR) are 
known to regulate a complex network of phase I and phase II metabolic enzymes in 
response to xenobiotics. Importantly, CAR and PXR expression also correlate with 
CYP2B625 and CYP2A626 expression in liver, even in the absence of enzyme inducers 
and xenobiotics. Activators of CAR have also been shown to induce UGT2B genes in 
vivo27 and so CAR appears to play a role in basal and inducible regulation of the 
enzymes involved in efavirenz metabolism.  
 
Therefore, we hypothesised that inter-individual variability in CAR and PXR caused, for 
example, by polymorphisms, would result in additional inter-individual variability in 
CYP2B6, CYP2A6 and UGT2B7. Single nucleotide polymorphisms have been reported 
in PXR28 and CAR29 genes and we have previously shown an association of a PXR 
SNP (63396C>T; rs2472677) with unboosted atazanavir plasma concentrations30 and 
an association of a CAR SNP (540C>T; rs2307424) with plasma concentrations of 
efavirenz. 31 
 
The aim of this study was to investigate the association of CYP2B6 (516G>T, 
rs3745274), CYP2A6 (CYP2A6*9B, rs8192726), UGT2B7 (735A>G, rs28365062; 
802T>C, rs7439366), CAR (540C>T; rs2307424) and PXR (44477T>C, rs1523130; 
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63396C>T, rs2472677; 69789A>G, rs763645) polymorphisms with discontinuation 
within 3 months of initiating efavirenz-containing regimens. In addition, the association 
with demographic factors including ethnicity, smoking habits and gender were also 
investigated. 
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Patients and Methods 
Patients 
A total of 373 patients who were on stable efavirenz containing Highly Active 
Antiretroviral Therapy (HAART) for at least 3 months (n=242; control group) or who 
discontinued efavirenz containing HAART within 3 months (n = 131; early 
discontinuation group) were included in this cohort study.  
 
We included patients of the cohort of the German Competence Network for HIV/AIDS 
(KompNet Cohort) with documented stable efavirenz treatment for at least 3 months 
and compared with those who discontinued efavirenz containing HAART within 3 
months. A further inclusion criterion was the availability of already stored EDTA-
samples. All concomitant medications were documented and patients were excluded 
from the analysis if receiving drugs with known drug interactions. No patients were 
receiving anti-TB treatments. 
 
Out of 480 patients with stable efavirenz containing HAART identified as a potential 
control group, stored EDTA samples were available from 255 patients. In 13 of these 
patients genotyping for one or more SNP was not successful. Therefore 242 patients on 
stable therapy were included in the final analysis. The median duration of efavirenz 
therapy in this group was 48 months (range 5 – 99 months). 213 patients were identified 
with early discontinuation of efavirenz-containing HAART, therefore fulfilling the 
inclusion criteria. In 131 patients EDTA samples were available and were therefore 
included in the analysis. The median duration or efavirenz exposure in this group was 
1.1 month (range 0.2 – 3 months).  
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Whole blood was provided by the KompNet Cohort. In this prospective multicenter, 
German-wide cohort semi-annual follow-up visits are documented and clinical and 
demographic data are collected. EDTA-samples are taken at enrolment and three years 
afterwards, serum samples are collected at every follow up visit. Demographic and 
clinical data were collected on: age, gender, weight, height, adherence (evaluated 
through pharmacy reports), ethnicity and qualitative smoking status. 32 Ethical approval 
was granted by the ethics committee of the Ruhr-Universität Bochum, Germany, and 
local ethics committee approval and informed consent was obtained at each site.  
 
Genotyping 
Total genomic DNA was isolated using the QIAamp DNA mini kit according to the 
manufacturer’s instructions. Following extraction, purity was assessed by comparing the 
A260 and A280 ratio. DNA was quantified using PicoGreen® (PG) dsDNA Quantitation 
Reagent (Molecular Probes, CA, USA) and normalised to 20 ng/μL. For CYP2B6 pre-
amplification was first conducted to discriminate from the CYP2B6 pseudogene 
(CYP2B7) by modification of previously reported methods.11 Genotyping for CYP2B6 
(516G>T), CYP2A6 (*9B), UGT2B7 (735A>G, 802T>C), CAR (540C>T) and PXR 
(44477T>C, 63396C>T, 69789A>G) was then performed by real-time PCR allelic 
discrimination using standard methodology (95°C for 15 minutes followed by 40 cycles 
of 95°C for 15 seconds and 60°C for 1 minute) in a DNA Engine Opticon ® 2 system 
(MJ Research Inc., USA). For CYP2B6 516G>T (rs3745274), CYP2A6*9B (rs8192726), 
CAR 540C>T (rs2307424), PXR 44477T>C (rs1523130) and PXR 7635A>G 
(rs6785049) Applied Biosystem pre-validated assays were utilised. The assay IDs were 
C___7817765_60, C__29560333_20, C__25746794_20, C___9152783_20 and 
C__29280426_10, respectively. For UGT2B7 735A>G (rs28365062) the forward primer, 
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reverse primer, A probe and G probe were 
CCTAAAGTAATTATCTTGTGTCATCCACCTT, CGTCAGCTTTCCCCATTGTCT, 
ACCCACTACATTATCTGT-VIC and CCCACTACGTTATCTGT-FAM, respectively. For 
UGT2B7 802T>C (rs7439366) the forward primer, reverse primer, C probe and T probe 
were CTGACGTATGGCTTATTCGAAACTC, TGGAGTCCTCCAACAAAATCAACAT, 
AGTGGATGAGGAAACTT-VIC, and AGAGTGGATAAGGAAACTT-FAM, respectively. 
For PXR 63396C>T (rs2472677) the forward primer, reverse primer, C probe and T 
probe were GCACAAACATTTTCAATTTCAATGAAGTTCA, 
CATTCGGAAGACTTATTCTATTCCTGTCT, CCATATTTTTTCTGATTAAA-VIC and 
CCATATTTTTTTTGATTAAA-FAM, respectively. 
 
Statistical analysis 
All data are given as frequency number (percentage) unless otherwise stated. 
Genotypes were tested for Hardy-Weinberg equilibrium by Chi-square test of observed 
versus predicted (from allele frequency) genotype frequencies. Statistical significance 
was assessed using the Chi-square test, Cramer’s V test or the linear by linear test for 
differences in qualitative variables. Univariate and multivariate associations were 
assessed with SPSS v16 (SPSS Inc., Chicago IL, USA) using logistic regression with 
backward method. Continuous variables are expressed as Median (Interquartile Range, 
IQR). A statistical trend was defined as a P value <0.1. Statistical significance was set 
at P <0.05. 
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Results 
This was a cohort study and all patients were recruited between 01.01.2006 - 
01.10.2009.  242 patients, who were on stable efavirenz containing HAART for at least 
3 months, were included in the control group and 131 patients were in the early 
discontinuation group (discontinuation of efavirenz containing HAART within 3 months). 
Treatment was discontinued for unknown reason in 55 patients (42%), for self reported 
CNS related side effects in 72 cases (55%), virological failure in one case (1%), 
elevated liver enzymes or other toxicities in four cases (3%). No documented cases of 
depression were encountered in these patients. Baseline characteristics of patients 
entered in the study are presented in Table 1. 
 
The backbone therapy was comparable between the discontinuation group and the 
control group. Preferential NRTI-based backbone therapies consisting either of 
tenofovir/emtricitabine or lamivudine/zidovudine were used. The remaining patients 
were receiving alternative backbone or NRTI-free therapies. Within the early 
discontinuation group, 42 of 131 patients were taking lamivudine/zidovudine (or 
zidovudine) (32%) and 59 of 131 patients were taking tenofovir/emtricitabine (45%). 
Within the control group 63 of 242 patients were taking lamivudine/zidovudine (26%) 
and 114 of 242 patients were receiving tenofovir/emtricitabine (47%).  
 
Association of demographics and backbone with early (<3 month) treatment 
discontinuation 
A higher proportion of white patients (39.2%; 109 out of 278) discontinued within 3 
months than compared to black patients (23.2%; 22 out of 95; p = 0.005). Smokers 
exhibited a lower frequency of discontinuation (30.9%; 73 out of 236) compared to non-
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smokers (42.3%; 58 out of 137; p = 0.026). No other associations (p < 0.05) or trends (p 
<0.10) were evident with demographic factors such age, sex, weight, height or BMI, 
even when stratified for ethnicity. 278 patients out of 373 had zidovudine, 
zidovudine/lamivudine or tenofovir/emtricitabine as backbone therapy. Frequency of 
zidovudine/lamivudine (or zidovudine) administration did not differ between patients that 
discontinued (42 out of 131; 32%) and patients that were stable on efavirenz (63 out of 
242; 26%), p = 0.21. Similarly, frequency of tenofovir/emtricitabine administration did 
not differ between patients that discontinued (59 out of 131; 45%) and patients that 
were stable on efavirenz (114 out of 242; 47%), p = 0.71. 
 
Allele frequencies according to ethnicity 
The frequency of the allelic variants in white and black patients are summarised in 
Table 2. Differences in frequency of the variant alleles between ethnicity (black ethnicity 
as reference) were evident for CAR rs2307424C>T (Odds ratio [OR] = 2.69; P = 
0.0001), CYP2B6 516G>T (OR = 0.73; P = 0.087 ), CYP2B6 983T>C (OR = 0; N/A), 
UGT2B7 802T>C (OR = 2.4; P = 0.0001), PXR 7635A>G (OR = 0.14; P = 0.0001), PXR 
44477T>C (OR = 7.38; P = 0.0001) and PXR 63396C>T (OR = 1.77; P = 0.009). 
 
Association of genetic factors with early (<3 month) treatment discontinuation 
When considering the entire population, CYP2B6 516G>T was statistically associated 
with early (<3 month) treatment discontinuation. Discontinuation rate was 33.5% (57 out 
of 170) in the 516GG group compared to 32.5% (55 out of 169) in the 516GT group and 
44.1% (15 out of 34) in the 516TT group (p = 0.03). Patients characterised by T 
homozygosity had a higher probability of early treatment discontinuation (55.9% vs 
33%; p = 0.008). A trend towards higher frequency of discontinuation among patients 
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characterised by CAR rs2307424 CC was also observed, with 38.9% (74 out of 190) of 
CC patients vs 30% (54 out of 180) of CT/TT patients discontinuing therapy before three 
months (p=0.071; CAR genotype data were unavailable for 3 patients). Patients with TT 
genotype for PXR 63396C>T had trend towards higher frequency of discontinuation 
(41.5%, 51 out 123) compared to patients with CT/CC genotype (32%; 80 out of 250; p 
= 0.072). Similarly, for UGT2B7 802T>C, patients with TC or CC genotype had trend 
towards higher frequency of discontinuation (37.5%; 101 out of 269) compared to 
patients with the TT genotype (28.2%; 29 out of 103; p = 0.089; UGT2B7 802 genotype 
was unavailable for 1 patient). No association (p < 0.05) or trend (p < 0.10) was 
observed for other polymorphisms. 
 
When considering only white patients (n = 278) patients with CYP2B6 516 TT had 
higher discontinuation rate (58.3%, 14 out of 24) compared to patients with CYP2B6 
516 GG/GT (95 out of 254 patients, p = 0.045). Moreover, white patients with CAR 
rs2307424 CC had a frequency of early discontinuation of 46.3% (56 out of 121) vs 
32.5% (50 out of 154) for CT/TT patients (p = 0.019). In black patients CYP2B6 516 TT 
genotype was associated with higher discontinuation rate (50%; 5 out of 10) than 
CYP2B6 516 GG/GT patients (20%; 17 out of 85; p = 0.033). No other associations (p < 
0.05) or trends (p < 0.10) were evident in either white or black patients.  
 
Multivariate analysis by binary logistic regression 
Multivariate logistic regression in the entire cohort confirmed the independent 
association of CYP2B6 516 and CAR rs2307424 genotypes with early (<3 month) 
treatment discontinuation. In addition to these genetic factors, ethnicity and smoking 
status were also identified as independent predictors. As shown in Table 3 the following 
 12
parameters were independently associated with treatment discontinuation: CYP2B6 
516TT (OR, 2.81; 95% Confidence Interval (CI), 1.34 to 5.9; p = 0.006), CAR 
rs2307424CC (OR, 1.92; 95% CI, 1.2 to 3.07; p = 0.007), black ethnicity (OR, 0.27; 
95% CI 0.14 to 0.50, p = 0.0001) and smoking status (OR, 0.45; 95% CI, 0.28 to 0.74; p 
= 0.002). 
 
Composite analysis for genetic and demographic risk factors 
To further confirm the association of these two polymorphisms with early discontinuation 
the CYP2B6 516T and CAR rs2307424 C alleles were classified as discontinuation-
associated alleles. As shown in Figure 1A, the number of high discontinuation-
associated alleles correlated with higher discontinuation. The rate of treatment 
discontinuation was: 25% (4 out of 16) for patients with no discontinuation-associated 
alleles, 29.6% (24 out of 81) for patients with one discontinuation-associated allele, 
32.4% (48 out of 148) for patients with two alleles, 39.4% (43 out of 109) for patients 
with three alleles and 56.2% (9 out of 16) for patients with four alleles (p = 0.023; CAR 
genotype data were unavailable for 3 patients). 
 
As shown in Figure 1B, the number of early discontinuation risk factors harboured by a 
patient (including CYP2B6 and CAR genetics, each allele counting as one risk factor; 
ethnicity; and smoking status) was associated with early discontinuation. The rate of 
early treatment discontinuation was 0% (n=1) for patients with no risk factors, 16.7% (3 
out of 18) for patients with one risk factor, 23% (16 out of 69) for patients with two risk 
factors, 31% (45 out of 145) for patients with three risk factors, 43.9% (43 out of 98) for 
patients with four risk factors, 51.4% (19 out of 37) for patients with five risk factors and 
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100% (n=2) for patients with six risk factors (p = 0.0001; CAR genotype data were 
unavailable for 3 patients). 
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Discussion 
Several studies have described an elevated frequency of CNS side effects in patients 
treated with efavirenz-based regimens, leading to treatment discontinuation primarily in 
the first week of treatment.3, 5-7 Inter-individual variability in metabolism and disposition 
genes for efavirenz may influence onset of side effects and therefore therapy 
discontinuation. CYP2B6 516 has been identified as a major predictor of efavirenz 
plasma concentrations12-19 and a correlation between frequency of CNS side effects in 
white patients and slow-metaboliser genotypes (CYP2B6 516TT and 983TT) was 
recently described.33 In the current cohort TT homozygosity for the CYP2B6 516 G>T 
polymorphism was independently associated with early treatment discontinuation.  
 
A novel association between a CAR polymorphism (rs2307424) and plasma efavirenz 
concentrations was recently reported by some of the investigators involved in the 
present study.31 The discontinuation data presented here extends these findings to a 
clinical phenotype, showing significant association of CC genotype with early treatment 
discontinuation. These findings strengthen the role of CAR in efavirenz disposition and 
pharmacokinetics, presumably through its role in the regulation of CYP2B6.  
 
A genetic composite of these two polymorphisms (CYP2B6 516 C>T and CAR 
rs2307424) was assessed and patients with more discontinuation-associated alleles 
(also the same as the high concentration-associated alleles 31) had a higher rate of 
discontinuation. This finding reinforces the hypothesis that early treatment 
discontinuation is associated with higher plasma concentrations. However, it must be 
noted that plasma efavirenz concentrations are higher in black patients than in white 
patients34, yet treatment discontinuation rates appear to be lower in black patients.35 In 
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the present study, white patients had a higher frequency of early discontinuation than 
black patients. Furthermore, the frequency of CYP2B6 and CAR alleles associated with 
higher plasma efavirenz concentrations are more frequent in black patients. We 
hypothesise that this apparent paradox may be explained by inter-ethnic variability in 
other unknown genes involved in the aetiology of CNS toxicity. 
 
Smoking status was also identified as being independently associated with early 
treatment discontinuation. We previously reported a trend towards an association 
between smoking and efavirenz plasma concentrations in the German Competence 
Network for HIV/AIDS19 and in a Chilean cohort.31 Interestingly, nicotine has previously 
been shown to activate nuclear receptors such as PXR and CAR36 and induction of 
CYP2B6 has been described.37 Furthermore, nicotine and efavirenz have an 
overlapping elimination pathway, both metabolised by CYP2B6 and CYP2A6, providing 
another putative mechanisms for the interaction.38 Nicotine exposure has also been 
shown to influence blood-brain barrier permeability in-vivo39, 40 and may therefore have 
an effect on efavirenz diffusion in CNS, independently of effects on pharmacokinetics.  
 
It must be noted that a major limitation of the current study is that the reasons for early 
discontinuation were not known for 42% of the cohort. However, of those discontinuing 
therapy for known reason, 94.7% discontinued due to CNS toxicity. Other reasons for 
an early treatment discontinuation (e.g. virological failure) usually lead to later (> 3 
months) discontinuation or modification of therapy. For this reason it seems likely that in 
the majority of patients the reason for the treatment discontinuation was CNS toxicity. 
Moreover, the reported associations were also present when univariate logistic analysis 
was conducted for patients that discontinued due to known CNS toxicity (n = 72), CAR 
 16
rs2307424CC (OR = 1.86, p = 0.037), CYP2B6 516TT (OR = 2.1, p = 0.122) and black 
ethnicity (OR = 0.42, p = 0.013). A potential additional limitation of this study is that no 
information was collected with respect to their adherence to medication.   
 
In conclusion, our findings indicate that genetic variability in genes involved in the 
metabolism and disposition of efavirenz are determinants of early (<3 month) treatment 
discontinuation. These data provide evidence that smoking status may be associated 
with discontinuation. In-vitro studies to identify the mechanisms underpinning these 
associations and to identify toxicological targets in the brain are now warranted. 
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Table 1: Baseline characteristics of patients with stable efavirenz therapy and with early treatment discontinuation of 
efavirenz. 
 
 On Therapy > 3 months 
 
On therapy < 3 months 
 
Total 
 
Number of patients 242 131 373 
Male Gender 269 104 293 (78.6%) 
White Ethnicity 264 109 278 (74.5%) 
Median Age (IQR) 45 (40 - 51) 47 (41 - 53) 46 (26 - 82) 
Median BMI (IQR)  23.5 (20.5 – 27.5) 23.5 (20.5 – 28) 24 (21-28) 
Smoking 73 (55.7%) 163 (67.4) 236 (63.3%) 
Median Years Since 
Diagnosis (Range) 
6 (1 - 12) 6 (1 - 12) 6 (1 - 12) 
Viral load (Range) <50 (<50 – 8 x 105) 325 (<50 – 1 x 106) <50 (<50 – 1 x 106) 
CD4 count (Range) 449 (12 – 3233) 325 (0 – 1260) 407 (0 – 3233) 
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Table 2. Allele frequencies in patients considering ethnicity. Frequency of the variant allele, odds ratio (OR) and p value 
are given.   
 
Polymorphism Variant allele in white (%) 
Variant allele in 
blacks (%) OR 
p 
value 
CYP2B6 516G>T 167/556 (30%) 70/190 (37%) 0.73 0.087 
CYP2B6 983T>C 0/556 (0%) 8/190 (4%) N/A N/A 
CAR rs2307424C>T 180/550 (32,7%) 29/190 (15%) 2.69 0.0001
PXR 44477T>C 329/556 (59.1%) 30/190 (15.7%) 7.38 0.0001
PXR 63396C>T 339/556 (60.9%) 89/190 (46.8%) 1.77 0.009 
PXR7635A>G 237/556 (42.6%) 158/188 (84%) 0.14 0.0001
CYP2A6*9B 40/556 (7.8%) 8/190 (4.2%) 1.78 0.17 
UGT2B7 735A>G 69/556(12.4%) 31/190 (16.3%) 0.68 0.101 
UGT2B7 802T>C 296/556 (53.2%) 61/188 (32.4%) 2.4 0.0001
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Table 3. Univariate and multivariate backward logistic regression for the identification of factors associated with early 
treatment discontinuation of efavirenz.  
 
 
 
 
 
 
 
 
 
 
 
*n.d = not done; Rows with significant p value (p <0.05) in the multivariate analysis are expressed in bold. 
Constant of the final multivariate model = 0.74 p = 0.21 
Measure of goodness of fit was conducted using Hosmer and Lomeshow test: χ2 = 4.8 p = 0.56. 
 
Covariate Univariate 
 
Multivariate 
 Odds ratio (95% CI) P value Odds ratio (95% CI) P value 
Gender (Female) 0.92 (0.55 to 1.56) 0.77  - 
Ethnicity (Black) 0.47 (0.27 to 0.80) 0.05 0.27 (0.14 to 0.50) 0.0001 
Age  1 (0.99 to 1) 0.25  - 
Height (cm) 0.99 (0.97 to 1.01) 0.57   
Weight (kg) 0.99 (0.98 to 1.01) 0.58   
Smoking 0.61 (0.39 to 0.94) 0.03 0.45 (0.28 to 0.74) 0.002 
CYP2B6 516TT 2.56 (1.25 to 5.2) 0.01 2.81 (1.34 to 5.90) 0.006 
CYP2B6 983 C carrier  0.25 (0.031 to 2.12) 0.21  - 
CAR rs2307424CC 1.49 (0.96 to 2.3) 0.07 1.92 (1.20 to 3.07) 0.007 
PXR 63396 C carrier 0.66 (0.43 to 1.04) 0.07 n.d.* 0.112 
CYP2A6*9B carrier 1.4 (0.75 to 2.65) 0.29   
UGT2B7 735 G carrier 0.75 (0.45 to 1.25) 0.28   
UGT2B7 802 C carrier 1.53 (0.93 to 2.5) 0.09 n.d.* 0.22 
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Figure 1 
Barchart to represent % of patients discontinuing treatment within 3 months and number 
of discontinuation-associated alleles (CYP2B6 516T and CAR rs2307424C, A) and 
number of discontinuation-associated risk factors (CYP2B6 516T and CAR 
rs2307424C, white ethnicity, and smoking; B).  
 
